Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
about
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuumSystematic review of dasatinib in chronic myeloid leukemiaOncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinomaEnantioselective total syntheses of plectosphaeroic acids B and C.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Therapeutic modulators of STAT signalling for human diseasesDasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.Bioactive Cycloperoxides Isolated from the Puerto Rican Sponge Plakortis halichondrioidesThe R(h)oads to Stat3: Stat3 activation by the Rho GTPases.Deletion of STAT5a/b in vascular smooth muscle abrogates the male bias in hypoxic pulmonary hypertension in mice: implications in the human disease.Src family kinases and paclitaxel sensitivity.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancerHypothesis: neuroendocrine mechanisms (hypothalamus-growth hormone-STAT5 axis) contribute to sex bias in pulmonary hypertension.Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.Resistance to HSP90 inhibition involving loss of MCL1 addiction.Amphidinolide B: total synthesis, structural investigation, and biological evaluation.Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerFusion in the ETS gene family and prostate cancer.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Stat5 as a diagnostic marker for leukemia.Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.Multiple roles of Lyn kinase in myeloid cell signaling and function.Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cellsUrine markers in monitoring for prostate cancer.Overcoming resistance in chronic myelogenous leukemia.Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.Septin roles in tumorigenesis.STAT signaling in the pathogenesis and treatment of myeloid malignancies.ERG protein expression as a biomarker of prostate cancer.Discovery bioanalysis and in vivo pharmacology as an integrated process: a case study in oncology drug discovery.Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of SeliciclibIdentification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
P2860
Q24594356-D650BFFA-3AF9-4117-A6EC-B9AA669FFB18Q24596026-780CFD31-44B7-426D-ABB3-8647409C2826Q28474516-BFBEF211-C024-4651-9374-00FF9FACDFB0Q30556998-DF2BFF6C-D643-4293-B50E-1397A5F5B511Q33397085-55C6D441-27A5-4227-B80F-A8507EDDA7F2Q33684732-77CD4B7D-6817-4C9B-8398-761B4E7A3E04Q34109861-6B72B1E2-D87A-4BFC-B49C-187190B2077DQ34309928-8D857CF3-5A38-4DDA-912A-167C157BB17DQ34541090-A833DD30-4DB0-49EC-A0FF-8B7A52A86652Q34565041-7B2C12EB-A468-49EC-82AE-622A6FAD4748Q35086590-74DEF315-6F17-498E-9924-C89A93C15988Q35192830-1750919D-043E-480E-97BE-270DCD3ED168Q35214722-3E5C5249-FF0E-4638-A9AB-4BBB2E53B42DQ36140620-57F4E1E6-F462-4844-B2A1-A280C7263951Q36546746-6BA2375F-9CD7-49FF-91AD-4A0E56AE1EB3Q36568290-79339820-ACF8-4E9F-BA12-21388C97432EQ36610777-0A4BFE78-2409-4573-9AC8-57C798B2A34FQ36693223-53CEA4E0-FC61-4DF6-BF24-4AB953A87AC0Q36762412-C291A5C1-7E91-4504-A2A7-041C9E8958A8Q36781833-72DCA484-8F6B-4CED-8BA3-0B5567E3DC77Q36785930-A3EAE6D9-B18B-4AC2-8DED-7B0EBE5EBE94Q36882701-5D20B760-3B5E-48C3-9933-5818FEEACFECQ36901964-BEFD39B6-C7F2-4A2B-8F13-9736A0613335Q37035281-EBC6D691-76C8-46DC-B018-776FA477053AQ37326151-BB2A203C-6DF5-4F69-99D4-E781BFE03840Q37327244-8D028D3C-5FCF-440D-9620-F78C46A705ADQ37416257-8EC6C585-C13F-4EAF-9EB8-15979D8468B0Q37450433-81F38EF9-6A62-4FE6-BF88-4128E2143458Q37571461-F5DD69B3-BB53-4E7A-8EE4-1709218C82DAQ37626054-32C6C152-E7F6-4EEE-AC26-00E6B93909BEQ37787243-114777CA-D043-426B-87B5-E2450CACE02AQ37870181-8BFECD70-01E2-4AA3-A007-463138D55A4FQ37899208-FF7A0040-19CC-49CB-BEA5-747F3DB14DAAQ38140880-43BA4F46-97C9-4DE7-9DAA-F31D914DEB89Q38165243-96C589BB-8369-4478-BE78-E89929EA63B5Q38763889-224BD41C-4AF9-4208-BBB3-C8919007FC68Q38877559-E50D5CFD-850C-4042-B209-2ED2AEA83876Q39147275-7BD885C6-D574-4238-A942-DBE1E13488A3Q39386402-63F7CD4B-5031-4D30-AB98-4AD1EC7752C4Q39434177-853C506F-4705-462E-8EC3-6FA1A800726E
P2860
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Dasatinib (BMS-354825) inhibit ...... ic myelogenous leukemia cells.
@en
type
label
Dasatinib (BMS-354825) inhibit ...... ic myelogenous leukemia cells.
@en
prefLabel
Dasatinib (BMS-354825) inhibit ...... ic myelogenous leukemia cells.
@en
P2093
P1476
Dasatinib (BMS-354825) inhibit ...... ic myelogenous leukemia cells.
@en
P2093
Ann Williams
Francis Y Lee
Kapil Bhalla
Richard Jove
Sangkil Nam
P304
P356
10.1158/1535-7163.MCT-06-0446
P577
2007-04-01T00:00:00Z